Chemokines are responsible for directing leukocyte migration and triggering firm arrest by activating integrins on leukocytes. It is now apparent that chemokines have critical biological roles beyond chemo-attraction. Throughout this thesis, I describe the importance of the CCL5/CCR5 axis in the context of the immune response and cancer biology. Specifically, CCL5 invokes dose-dependent distinct signalling events downstream of CCR5 activation in T cells. I show that nM concentrations of CCL5 mediate CD4+ T cell migration that is partially dependent on mTOR activation. CCL5 induces phosphorylation and de-activation of the repressor 4E-BP1, resulting in its dissociation from the eukaryotic initiation factor-4E to initiate protein translation. I provide evidence that CCL5 initiates rapid translation of cyclin D1 and MMP-9, known mediators of cell migration. The data demonstrated that up-regulation of chemotaxis-related proteins may “prime” T cells for efficient migration. During an immune response, recently recruited T cells are exposed to high CCL5 concentrations. The propensity of CCL5 to form higher-order aggregates at high, µM concentrations, prompted studies to investigate their effects on T cell function. I show that at these high doses, CCL5 induces apoptosis in PM1.CCR5 and MOLT4.CCR5 T cell lines. CCL5-induced cell death involves the cytosolic release of cytochrome c and caspase-9/-3 activation. Furthermore, I identified Tyrosine-339 as a critical residue within CCR5, suggesting that tyrosine phosphorylation signalling events are important in CCL5-mediated apoptosis. Our data suggest that CCL5-induced cell death, in addition to Fas/FasL mediated events, may contribute to clonal deletion of T cells during an immunological response. I subsequently examined the possible pathological consequence of aberrant CCL5/CCR5 signalling in breast cancer. Exogenous CCL5 enhances MCF-7.CCR5 proliferation, which is abolished by anti-CCR5 antibody and rapamycin. CCL5 induces the formation of the eIF4F translation initiation complex, and mediates a rapid up-regulation of cyclin D1, c-Myc and Dad-1 protein expression. Thus, our data demonstrate the potential for breast cancer cells to exploit downstream CCL5/CCR5 signalling pathways for their proliferative and survival advantage. Taken altogether, each of these studies reinforces the notion that chemokines are not only potent chemotactic mediators, but are key effectors in diverse developmental, immunological and pathological processes.

Over the last 20 years, advances in our understanding of the pathophysiology of severe traumatic brain injury (TBI) and in particular the contribution of secondary injury to poor outcome, has served to improve clinical management and reduce the mortality in these patients. However despite many promising preclinical studies there has been a failure to introduce a specific therapeutic intervention to further improve outcome. Inflammation, with cytokine release and leucocyte infiltration, is a significant secondary injury processes. However the inflammatory response to brain injury, its control and modulation remain incompletely described. Chemotactic cytokines, known as chemokines, are mediators of leucocyte recruitment and activation. Expression of chemokines and the resultant recruitment of leucocytes into the brain are generally thought to be integral to the enlargement of cerebral contusions which accompany clinical deterioration following severe TBI. Previous studies indicated that the main neutrophil chemokine, macrophage inflammatory protein-2 (MIP-2/CXCL2) and the monocytic chemokine, monocyte chemoattractant protein-1 (MCP-1/CCL2) are derived from glial. However the origin of these chemokines following TBI, has not been established. Furthermore, little is known about the modulation of these chemokines: The relationship of serum levels of pro-inflammatory mediators such as the human neutrophil chemokine, interleukin-8 (IL-8/CXCL8; a functional homologue of MIP-2/CXCL2), MCP-1/CCL2 and soluble interleukin-6 receptor (sIL-6R) to contusion enlargement has not been investigated. In this thesis, I investigated chemokine expression and modulation both in in-vitro, in-vivo models and in a clinical study. Initially, I compared chemokine expression in rodent and human glial cell cultures and investigated the modulation of chemokine expression by interleukin-6, the glucocorticoid dexamethasone and the immunosuppressant agent FK506. To investigate chemokine expression in-vivo I established the rat lateral fluid percussion injury (LFPI) model of TBI and measured MIP-2/CXCL2 and MCP-1/CCL2 expression in the brain following injury. Inhibition of this expression by dexamethasone and FK506 was then investigated. To identify the cellular source of chemokine expression I developed an immunohistochemical protocol for MIP-2/CXCL2 and MCP-1/CCL2. Finally, in a clinical study of serum chemokine and sIL-6R concentrations after severe TBI, I examined the relationship between these inflammatory mediators and clinical deterioration. Rat glia (microglia and astrocytes) produce chemokines with a response profile that was qualitatively similar to that of human derived cells. These chemokines were increased in the ipsilateral hemisphere following TBI. Surprisingly, immunohistochemical studies identified marked chemokine expression localised to cells with the morphology of degenerating neurones in contused tissue, rather than in glia. Furthermore, while dexamethasone significantly inhibited both MIP-2/CXCL2 and MCP-1/CCL2 expression in a rat astrocyte derived cell line, only MCP-1/CCL2 expression was reduced by steroid treatment in-vivo. Clinically, serum IL-8/CXCL8, MCP-1/CCL2 or sIL-6R were not significantly different in patients that deteriorated due to contusion enlargement from those that remained stable. However these inflammatory mediators were significantly increased in those patients that died. These studies indicate that astrocytes may not be the major source of chemokines following TBI and highlight the need for caution when inferring pathophysiological mechanisms from in-vitro studies.

Chemokine-induced macrophage recruitment into the vascular wall is an early pathological event in the progression of atherosclerosis. Macrophage activation and chemotaxis during cell recruitment are mediated by chemokine ligation of multiple G- protein coupled receptors. The Regulator of G-Protein Signalling-l (RGS-l) acts to down-regulate the response to sustained chemokine stimulation. Studies in this laboratory have shown Rgsl is up-regulated in atherosclerotic ApoE1- mice in association with atherosclerotic plaque progression and published findings have reported that RGS 1 is highly expressed in leukocytes. However an in vivo role for RGS-l in macrophage function or in atherosclerosis has not been investigated. This thesis aimed to address the hypothesis that RGS 1 has an important role in atherosclerosis and modulates the inflammatory response by controlling chemokine signalling and macrophage chemotaxis to atherosclerotic plaques. To investigate the role of RGS 1 in macrophage function and the development of atherosclerosis, Rgsrl- mice were characterised on the ApoE1- background. Flow cytometric analysis of leukocytes in blood, spleen and bone marrow indicated Rgsrl- ApoE1- mice had no significant differences in the numbers of monocytes or lymphocytes compared to ApoE1- mice. Rgsl was found to be highly expressed in macrophages from ApoE1- mice compared to B-Iymphocytes, where it has a non-redundant role, and other cells involved in plaque formation. Furthermore, Rgsl is up-regulated with monocyte- macrophage activation by innate stimuli. For the first time, RGS 1 'was shown to affect chemokine receptor signalling in macrophages in vitro. RgsrlApoE1- macrophages showed significantly enhanced chemotaxis to CCL2, CCL3 and CCLS and impaired homologous desensitisation to the chemokine CCLS in comparison to ApoE1- cells. To determine the role of RGS-l in leukocyte trafficking and atherosclerosis, a detailed atherosclerosis study was carried out. RgsrlApoE1- mice had significantly less lesion formation in the aortic roots at 9-weeks and in the aorta at 16-weeks on a chow diet in comparison to ApoE1- mice. This was accompanied with decreased macrophage content in the aortic root at 9-weeks. To further investigate aortic leukocyte recruitment, an Angiotensin IT-induced model of acute vascular inflammation was used. At 9 weeks of age, Rgsrl-ApoE1- mice had significantly less aortic CD4S+ leukocytes and cons' myeloid cells recruited to the aorta in comparison to ApoE1- mice. Collectively, these findings identify a new role for RGS-l in macrophage function and support a role for RGS-l in leukocyte recruitment and retention in the initial stages of atherosclerotic plaque formation. These results identify RGS 1 as a novel target for the treatment of acute vascular inflammation and early atherosclerosis.

A polpa dental é formada de tecido conjuntivo frouxo sendo constituída por diversas células, dentre as quais os fibroblastos são as mais numerosas. Ao serem submetidas a agressões diversas, estas células respondem com a liberação de substâncias, tais como citocinas e quimiocinas, que participam de maneira ativa no processo inflamatório. Assim sendo, este trabalho teve como proposição: 1. avaliar a capacidade de fibroblastos de polpa dental humana em cultura em produzirem as quimiocinas MIP-l\'alfa\' /CCL3 e SDF-1/CXCL12; 2. avaliar a produção destas quimiocinas pelos fibroblastos quando estimulados por Enterococcus faecalis morto por calor com relação à quantidade de bactérias por célula e 3. avaliar a liberação destas quimiocinas com relação ao tempo de estímulo. Para o estabelecimento das culturas, foi coletada a polpa de terceiro molar hígido de um paciente saudável. O tecido foi extraído, armazenado e picotado em meio de cultura para fibroblastos (DMEM), os quais foram utilizados a partir da quarta passagem. Após adesão das células a placas de 24 poços, o meio de cultura contendo Enterococcus .faecalis morto por calor numa concentração correspondente a 1, 10 e 100 bactérias por fibroblasto foi adicionado aos poços. Após 1, 6 e 24 horas, o sobrenadante das células foi coletado para a análise por ELISA. A análise estatística foi realizada aplicando-se o teste Kruskal-Wallis com nível de significância de 5%. A produção de MIP-l\'alfa\' /CCL3 e SDF-l/CXCL12 pelas células pôde ser detectada por ELISA. Os fibroblastos pulpares se mostraram capazes de produzir SDF-1 constitutivamente sendo que o estímulo bacteriano levou a uma diminuição estatisticamente significativa desta produção. A produção de MIP-l\'alfa\' também foi detectada tanto de maneira constitutiva como em resposta ao desafio microbiano. Enquanto a concentração intermediária de bactéria por fibroblasto (10:1) mostrou uma produção semelhante ao grupo controle, as concentrações de 1 e 100 bactérias por fibroblasto induziram aumento maior na primeira hora de estímulo. Essas diferenças, entretanto, não foram estatisticamente significativas. A capacidade dos fibroblastos secretarem quimiocinas, como MIP-l\'alfa\' e SDF-1, reforça a importância dessas células dentro do contexto de imunidade e inflamação pulpar, principalmente por serem as células mais numerosas deste microambiente. / Dental pulp is a connective tissue structure constituted by many different cell types. Among them, the fibroblasts are the most frequent ones. When challenged by different aggressive agents, these cells are able to release some substances like cytokines and chemokines, which are essential to trigger the inflammatory process. The aims of this study were: 1. to evaluate the ability of fibroblasts to produce the chemokines MIP-l\'alfa\'/CCL3) and SDF-1/CXCL12; 2. to evaluate the expression of these chemokines by fibroblasts when challenged by heat killed Enterococcus. faecalis in gradual concentrations and 3. to evaluate the production of these chemokines in a time course manner. The dental pulp from non-carious third molar was collected from a healthy patient. Explants were made and stocked in culture medium (DMEM) for fibroblasts growth. The cells were used since passage four. In a 24-well plate and after reaching confluence, culture medium alone or containing heat killed E. faecalis at proportion 1:1, 10:1 and 100:1 bacteria:fibroblast, were added to the fibroblasts. After 1, 6 and 24 hours, the supernatants were collected for analysis. The protein detection of MIP-l\'alfa\'/CCL3 and SDF-1/CXCL12 was performed by ELISA. For statistical analysis, data were assessed by Kruskal-Wallis followed by Miller post-test. Significance levels of 5% were adopted. Production of both chemokines was detected by ELISA. Pulp fibroblasts were able to produce SDF-1 constitutively. This production decreased with the increase in the number of heat killed E. faecalis increased (p < 0.05). Production of MIP-l\'alfa\' was detected in unchallenged and challenged cells. The median bacterial concentration (10:1) presented a profile production similar to that of unstimulated cells. Bacterial concentrations of 1 and 100 microrganisms/cell showed a highly enhanced production of MIP-l\'alfa\' at the first hour of stimulum; however, these data were not statistically significant (p > 0.05). Fibroblasts ability to produce chemokines, like MIP-l\'alfa\' and SDF-1, confirms their importance at immune and inflammatory events in dental pulp, specially being fibroblasts the most abundant cells at this microenvironment .

La myasthénie (Myasthenia Gravis) est une maladie neuromusculaire impliquant des auto-anticorps dirigés majoritairement contre le récepteur à l’acétylcholine (RACh) et entrainant une fatigabilité musculaire. Ces auto-anticorps pathogènes sont produits principalement par le thymus qui présente une hyperplasie caractérisée par le développement de centres germinatifs ectopiques. De récentes études ont démontré la surexpression de chimiokines dans le thymus des patients et la présence anormale de vaisseaux sanguins de type HEV (cellules endothéliales à paroi haute). L’objectif de ma thèse a été de mieux comprendre les mécanismes physio-pathologiques conduisant à l’hyperplasie thymique en étudiant le rôle des chimiokines dans la myasthénie.Nous avons tout d’abord démontré que le nombre de HEV thymiques est proportionnel au degré d’hyperplasie suggérant leur implication directe dans le recrutement des cellules périphériques. En analysant les chimiokines exprimées sur ces HEV, nous observons l’expression sélective de SDF-1/CXCL12. En parallèle, la présence de lymphocytes B, de cellules dendritiques myéloïdes ou plasmacytoïdes et de monocytes/macrophages exprimant le récepteur au SDF-1, CXCR4, a été observée au niveau des HEV. En périphérie, nous montrons une diminution de l’expression de CXCR4 ainsi que du nombre de mDC et de monocytes dans le sang des patients suggérant le recrutement de ces cellules dans le thymus.Le thymus des patients myasthéniques est aussi caractérisé par une surexpression de la chimiokine CXCL13 par les cellules épithéliales thymiques. Pour mieux comprendre les mécanismes conduisant à l’hyperplasie thymique, nous avons développé un modèle de souris transgéniques avec surexpression thymique de CXCL13. Dans le thymus de ces souris, nous observons une surexpression de CXCL13 et une augmentation de nombre de lymphocytes B, notamment pour les souris jeunes. Nous étudions maintenant si l’immunisation de ces souris avec du RACh purifié induit une myasthénie expérimentale associée à une hyperplasie thymique ; un nouveau modèle animal de la maladie qui se rapprocherait mieux de la pathologie humaine.Dans la myasthénie, le thymus est aussi caractérisé par une signature inflammatoire, avec notamment une surexpression d’interféron de type I (IFN-I). Nous démontrons que le Poly(I:C), une molécule mimant les effets des ARN double-brin, induit spécifiquement la surexpression du RACh-α par les cellules épithéliales thymiques humaines via la libération d’IFN-I. L’IFN-I entraine aussi la surexpression des chimiokines CXCL13 et CCL21 comme dans le thymus des patients myasthéniques. Chez des souris C57Bl6, mais pas chez des souris KO pour le récepteur à l’IFN-I, des injections de Poly(I:C) entrainent des modifications thymiques avec une surexpression spécifique de RACh-α, d’IFN-I et de chimiokines. En périphérie, ces injections entrainent l’apparition dans le sérum d’anticorps contre le RACh-α spécifiques de la myasthénie.L’ensemble de ces résultats suggère que dans le thymus des patients myasthéniques, le développement anormal de HEV exprimant du SDF-1 et la surexpression de CXCL13 joueraient un rôle central dans le recrutement de cellules périphériques. Ces cellules, une fois dans l’environnement inflammatoire caractéristique du thymus myasthénique, pourraient alors développer une réaction auto-immune contre le RACh. De nouvelles molécules thérapeutiques contrôlant l’expression de ces chimiokines ou l’angiogenèse pourraient diminuer le développement de l’hyperplasie thymique et éviteraient la thymectomie ou l’utilisation des glucocorticoïdes par les patients atteints de myasthénie. / Autoimmune myasthenia gravis (MG) is a muscular disease mediated by autoantibodies, mainly directed against the acetylcholine receptor (AChR). The pathogenic antibodies are especially produced in the thymus, which is often characterized by a hyperplasia with germinal centers. Recent studies demonstrated the overexpression of chemokines and the abnormal development of high endothelial venules (HEV) in the MG thymus. The aim of my thesis was to better understand the mechanisms that lead to thymic hyperplasia in MG by analyzing the role of chemokines in peripheral cell recruitment. We demonstrated that the number of HEVs correlated with the degree of hyperplasia suggesting a direct link between HEVs and peripheral cell recruitment. To define its mechanism of action, we examined which chemokines were expressed on thymic HEVs. We uniquely detected SDF-1 and observed that B cells, myeloid dendritic cells (mDCs), plasmacytoid DCs and monocytes/macrophages that expressed the SDF-1 receptor CXCR4 localized inside and around thymic HEV. In parallel we observed a decreased CXCR4 expression and a decreased number of mDCs and also monocytes in the periphery suggesting their recruitment to the MG thymus. As the MG thymus was recently characterized by the overexpression of CXCL13 in thymic epithelial cells (TECs), we investigated its contribution to thymic hyperplasia. We therefore generated a transgenic mouse model overexpressing in medullary TECs CXCL13 under the control of keratin 5. We demonstrated that transgenic K5-CXCL13 mice specifically overexpressed CXCL13 in the thymus, while no other tested chemokines were upregulated. Preliminary results showed that elevated levels of CXCL13 resulted in an increased number of B cells in the thymus of transgenic mice, which localized preferentially in loose aggregates in medullary areas. We are presently investigating if immunization with purified AChR induces experimental MG with thymic hyperplasia in these mice. Myasthenic mice with a hyperplastic thymus could present a new animal model for MG with a phenotype that is closer to the human disease than the current MG model. As the hyperplastic MG thymus displays the hallmarks of a viral signature, we investigated the effect of pathogen-associated molecules on thymic changes associated with MG. We demonstrated that dsRNA signaling induced by Poly(I:C) specifically triggers the overexpression of α-AChR in human TECs through the release of IFN-I. We also observed that IFN-I was able to upregulate CXCL13 and CCL21, similarly to what is observed in the MG thymus. In addition, Poly(I:C) injections in wildtype mice, but not in IFN-I receptor KO mice, specifically increase thymic expression of α-AChR and, in parallel, CXCL13 and CCL21 expression. In periphery, Poly(I:C) even induced an anti-AChR autoimmune response characterized by a significant production of serum anti-AChR antibodies and a specific proliferation of B cells. Overall the results obtained in the course of my PhD showed that the abnormal development of SDF-1-expressing HEVs and the CXCL13 overexpression play a central role in the recruitment of peripheral cells to the MG thymus. Once these cells have arrived in the inflammatory environment, which is characteristic for MG, they could develop an autoimmune reaction against AChR. New therapeutic molecules that control chemokine expression and angiogenic processes could diminish the development of thymic hyperplasia and avoid thymectomy or the use of corticoids.

: L’athérosclérose est une maladie inflammatoire chronique des grosses artères à localisation intimale. Elle est probablement la résultante d’une réaction inflammatoire mal contrôlée ayant pour but initial d’éliminer l’accumulation anormale de lipides au niveau de l’intima. Cette élimination est exercé par les monocytes/macrophages, dont l’infiltration et l’accumulation au niveau des lésions sont une étape cruciale de l’inflammation chronique locale provoquant en particulier la production de cytokines.Les mécanismes moléculaires responsables de cette accumulation monocytaire impliquent notamment les chimiokines et leurs récepteurs, acteurs clés de la mobilisation des leucocytes. Les souris génétiquement invalidées pour certaines chimiokines comme CCL2 et CX3CL1 ou pour leurs récepteurs respectifs sont partiellement protégées de l’athérosclérose. Par ailleurs, chez l’homme, des variations génétiques de CX3CR1 sont associées à une réduction du risque d’accidents cardiovasculaires. L’ensemble de ces résultats indiquent un rôle clé des chimiokines inflammatoires dans l’athérogenèse.L’objectif de cette thèse était de tester l’utilisation d’inhibiteurs des récepteurs de chimiokines comme outils thérapeutiques contre l’athérosclérose. Dans ce but, notre laboratoire a développé une molécule aux propriétés antagonistes du récepteur CX3CR1, marqueur utilisé pour la caractérisation phénotypique des monocytes. Nos travaux sur deux modèles murins d’athérosclérose mettent en évidence que le blocage de CX3CR1 par notre antagoniste réduit la taille des plaques d’athérosclérose formées sans modifier leur composition cellulaire ni le taux de cholestérol plasmatique circulant. Cette diminution est corrélée à une diminution du nombre d’une sous-population monocytaire circulante spécifique, ainsi qu’à une diminution de leurs propriétés d’adhérence et de survie. D’un point de vue curatif, l’antagoniste de CX3CR1 est capable de limiter la progression des plaques d’athérosclérose sans la prévenir totalement.L’utilisation d’un outil ciblant spécifiquement le récepteur CX3CR1 nous à permis d’une part de mieux comprendre le rôle de ce dernier dans les processus de monocytose et d’athérogenèse et d’autres part d’évaluer la faisabilité d’approches thérapeutiques visant à limiter le nombre de monocytes infiltrant les lésions d’athérosclérose. Les perspectives de ces travaux consistent d’une part à approfondir encore le rôle de CX3CR1 dans la mobilisation monocytaire, notamment au niveau de la moelle osseuse, et d’autre à utiliser l’antagoniste testé en association avec d’autres drogues ciblant les récepteurs de chimiokines impliqués dans l’athérogenèse, tels que CCR2 et CCR5. / Atherosclerosis account for nearly 30% of death in industrialized countries. It is a chronic inflammatory disease of the large arteries intima. It has been suggested that it is the result of an uncontrolled inflammatory reaction secondary to an abnormal accumulation of lipids in the intima. The lipid clearance is performed by monocytes / macrophages, Their infiltration and accumulation in atherosclerotic lesions is a critical step of a local chronic inflammation associated with an increased production of cytokines. The molecular mechanisms of the generation of atherosclerotic lesions involve monocytes, chemokines and their receptors which are key players controlling leukocytes mobilization. Mice genetically invalidated for chemokines such as CCL2 and/or CX3CL1 or their respective receptors are partially protected from atherosclerosis. Furthermore, in humans, genetic polymorphisms of CX3CR1 are associated with a reduced risk of cardiovascular events. Taken together, these results highlight a key role for inflammatory chemokines in atherogenesis. The aim of this thesis was to investigate wether inhibitors of chemokine receptors could play a role as therapeutic tools against atherosclerosis. To this end, our laboratory had developed an antagonist of CX3CR1, a crucial phenotypic and functional marker of monocytes. Our work, on two murine models of atherosclerosis, demonstrates that blocking CX3CR1 by our antagonist reduces the size of atherosclerotic lesions. This decrease is correlated with a lower number of circulating inflammatory monocytes, as well as a decrease in their adhesion and survival properties. Therefore, CX3CR1 antagonist coud be able to limit the progression of atherosclerotic plaques. Targeting CX3CR1 allowed us to understand the role of this receptor in the pathophysiology of atherogenesis by its effects on circulating inflammatory monocytes and to evaluate the feasibility of the use of this antagonist as a therapeutic tool to reduce atherosclerotic lesions. Perspectives of this work are firstly to deepen the role of CX3CR1 in monocyte mobilization, especially from the bone marrow, and secondly to test this antagonist in combination with others drugs targeting chemokine receptors involved in atherogenesis, such as CCR2 and CCR5 in order to better control the evolution of atherosclerotic lesions.

An animal model of respiratory infection was used to determine the effect of various factors, thought to influence the ability of the host to clear bacteria, on the host?s innate response to an NTHi lung infection. Mucosal immunisation with NTHi has previously been shown to enhance the clearance of NTHi from the lung in an animal model of infection through the increased recruitment of phagocytes. Comparisons of cytokine and chemokine kinetic profiles were made in order to determine differences between innate and acquired immune response and the way in which mucosal immunisation controls the innate immune response to NTHi. Increased production of proinflammatory cytokines and chemokines in the early stages of NTHi lung infection enhanced the ability to clear bacteria from the rat lung in the immune animals through the increased recruitment of phagocytes to the site. Mucosal immunisation was found to alter the cytokine and chemokine mRNA profiles of CD4+ and CD8+ cells, with increased levels of MCP-1 protein being detected in both types of immune cells. An antecedent viral infection has been shown to increase the chance of developing a respiratory bacterial infection. The NTHi model of respiratory infection was used to characterise the effect that a viral infection had on the host response to the host?s innate response to a bacterial infection and the ability to clear the bacteria. The host?s ability to clear NTHi from the rat lung was enhanced by an antecedent viral infection through alterations to the innate immune response and the cytokine and chemokine kinetic profiles. The use of a mutant strain of NTHi deficient in a component of Lipooligosaccharide (LOS), Phosphorylcholine (ChoP), was utilised as a tool to characterise the innate immune response to LOS. Animals challenged with the LOS mutant strain had a reduced inflammatory response to NTHi through the decreased production of pro-inflammatory cytokines and chemokines and the reduced recruitment of phagocytes to the site of infection. This thesis has contributed valuable information to enable a better understanding of the host?s innate immune response to respiratory infection. This study has identified the role of cytokines and chemokines in the innate response to a respiratory bacterial infection and the enhanced ability of the host to clear NTHi from the lung.

Tuberculosis is the second leading cause of morbidity and mortality worldwide due to an infectious disease. Development of a new tuberculosis (TB) vaccine would be facilitated by a better understanding of the mechanisms of protection induced by the current TB vaccine, Mycobacterium bovis BCG. Recombinant guinea pig (rgp)CCL5 and anti-rgpCCL5 were developed and characterized. The biological activity of rgpCCL5 was determined in a chemotaxis assay using T lymphocytes and pleural exudate cells. The specificity of rabbit anti-rgpCCL5 polyclonal antibody was confirmed by Western blot. RgpCCL5 was used to stimulate alveolar and peritoneal macrophages in vitro. and cytokine/chemokine gene expression was evaluated using real-time PCR. RgpCCL5 stimulated TNF&#945;, IL-1&#946;, CCL2, and CXCL8 mRNA expression and TNF&#945; protein production (as assessed in the L929 cell bioassay) in macrophages. The effect of BCG-vaccination on CCL5 expression and production in leukocytes infected with M. tuberculosis was examined in vitro and in vivo. Polyclonal anti-rgpCCL5 was used to develop an ELISA assay to quantify gpCCL5 protein levels, and real-time PCR was used to detect CCL5 mRNA. Leukocytes isolated from BCG-vaccinated guinea pigs and infected in vitro with virulent M. tuberculosis demonstrated significantly elevated gpCCL5 mRNA and protein compared to cells from naive animals. The response of gpCCL5 to M. tuberculosis in vivo was studied in tuberculous pleural effusions, where peak levels of CCL5 mRNA and protein were reached at day 4 post-induction. Disease severity, cellular differentiation, histology, and cytokine/chemokine mRNA levels in pleural cells and granulomas were analyzed on day 4 in guinea pigs induced with tuberculous pleurisy and treated with either rgpCCL5 or anti-rgpCCL5 by direct intra-pleural injection. In these studies, neutralizing CCL5 resulted in reduced macrophage accumulation, diminished levels of IFN&#947;, TNF&#945;, and CCL5 mRNA in pleural effusion cells, and reduced spontaneous lymphocyte proliferation. Together these studies suggest an important role for gpCCL5 in activating leukocytes during M. tuberculosis infection.

Thesis (M.S.)--Brigham Young University. Dept. of Chemistry and Biochemistry, 2008. / Includes bibliographical references (p. 49-53).

published_or_final_version / Paediatrics and Adolescent Medicine / Master / Master of Philosophy